Glioblastoma

NBM-BMX: Glioblastoma (TW, Phase 1b/Expansion → Phase 2)


ProgramPreclinicalPhase IPhase Ib/ExpansionPhase IIPhase III
Glioblastoma 
 
Phase I
Phase Ib/Expansion
Phase II
Phase III

NBM-BMX is a novel chemical entity designed to selectively inhibit histone deacetylase 8 (HDAC8). While non-selective HDAC inhibitors face limitations in clinical applications due to significant side effects, the development of isoform-selective inhibitors like NBM-BMX offers a promising alternative. NBM-BMX has demonstrated potent anti-proliferative effects across various cancer cell types, particularly in tumors with elevated HDAC8 expression.

NBM-BMX is a novel chemical entity designed to selectively inhibit histone deacetylase 8 (HDAC8). While non-selective HDAC inhibitors face limitations in clinical applications due to significant side effects, the development of isoform-selective inhibitors like NBM-BMX offers a promising alternative. NBM-BMX has demonstrated potent anti-proliferative effects across various cancer cell types, particularly in tumors with elevated HDAC8 expression.